KMT2A and leukemia: Inhibition of IRAK4 to regulate UBE2O markedly increases the chromatin occupation of wild-type and inhibits the proliferation of MLL leukemia, which provides us a paradigm to develop a novel therapy method for aggressive MLL leukemia and other cancers caused by improper translocation.